Neuroscience

This Theme’s Focus

To develop personalised treatments for patients with brain diseases to reduce disability and prolong a healthy life
We focus on rare inherited brain and muscle disorders, brain inflammation including multiple sclerosis, and traumatic brain injury

Neurological disorders affect one in six in the UK and are complex and highly variable, with limited treatment opportunities.

Stroke and dementia account for less than 15% of neurological disorders. Rare neurological disorders affect around one in 1,000, conditions of brain inflammation, including multiple sclerosis (MS) and autoimmune encephalitis (AE) affect around four in 1,000; whereas traumatic brain injury (TBI) is the leading cause of death in young adults and a major cause of disability affecting 50 million people every year worldwide.

NHS hospitals have seen more than a 20% increase in neurological admissions since 2016, which reflects advances in the management of acute neurological trauma and an ageing population. This leaves many patients with life-long disability, has substantial negative impact on quality of life, and costs the NHS over £4.4billion a year.

To address this, we want to use technological advances in genomics, metabolomics (the study of small molecules in the body, known as metabolites) and imaging to help us develop personalised medicine in rare neurological disorders, brain inflammation and traumatic brain injury.

We have established a region-wide hub for precision experimental medicine and early phase interventions in neurological diseases, recruiting participants across the East of England and nationally, reaching deep into deprived rural and coastal areas.

And our dedicated Patient and Public Involvement (PPI) panel helps us by providing detailed input into grant applications and shaping our research priorities. We have hosted visits from patients, friends and relatives, alongside traditional PPI outreach events. All of our clinical study groups include one or more PPI representatives.

Theme Lead

Professor Alasdair Coles

Medical adviser to the Multiple Sclerosis Society of the UK, and advises several pharmaceutical companies.
Email: ajc1020@medschl.cam.ac.uk

Meet our researchers

Here are some of the conditions we are researching:

Brain inflammation

Brain inflammation includes multiple sclerosis (MS) and encephalitis.

MS has many treatments but we don’t know much about their effectiveness outside short clinical trials, and there are no treatments that promote remyelination, which can prevent long-term neurodegeneration in MS.

Encephalitis can be viral or autoimmune. Treatments of these are different but diagnostic confirmation takes time, especially for autoimmune encephalitis (AE).

We aim to optimise treatments for multiple sclerosis (MS) and optimise how we detect and stratify (group) both viral and autoimmune encephalitis.

Rare inherited neurological diseases

A genetic diagnosis is not possible for around 40% of families with suspected neurogenetic disorders, even after whole genome sequencing. By providing a molecular diagnosis, we can then enable accurate genetic counselling, prenatal diagnosis and the diagnosis of unrecognised treatable disorders.

We also want to develop new treatments for inherited neurological disorders. The majority of neurogenetic disorders have no treatment, causing progressive disability and early death. Capitalising on our international leadership in mitochondrial biology, we will focus on mitochondrial disorders which affect one in 5,000 people.

Traumatic brain injury (TBI)

Traumatic brain injury is responsible for many of the 11,000 trauma deaths per day globally. We have developed innovative therapies and identified novel monitoring tools to target the management of intracranial pressure, breaking the vicious cycle of brain swelling. Our work has contributed to reducing the likelihood of dying from brain injury. Specifically, decompressive craniectomy is now used routinely in the UK and has saved 22 additional lives out of 100, with 60% of survivors independent at home.

However, current treatment paradigms are generic and provide no framework for developing and using personalised medicine approaches (particularly in patients with mild injury). They also take no account of the growing evidence that TBI can trigger neurodegeneration. We aim to develop personalised medicine in TBI, and develop and evaluate novel experimental therapies for specific patients groups, to further reduce mortality and disability in survivors.

Latest News

Prestigious lectureship award for NIHR BRC: Cambridge stroke researcher

March 21, 2024

Professor Peter Hutchinson (right) receiving the medal from Professor Tor Ingebrigtsen

Top research award for Neuroscience Theme co-lead Prof Hutchinson

November 8, 2023

Surgery at CUH - Image from Cambridge University Health Partners

New study recommends replacing skull section after brain bleed treatment

May 10, 2023

Cambridge researcher wins prestigious award for rare eye disease gene replacement therapy research

April 20, 2023

Patient in hospital bed - Parentingupstream from Pixabay

Cognitive impairment from severe COVID-19 equivalent to 20 years of ageing, research finds

May 3, 2022

AI generated brain image - David_SMC from Pixabay

Study suggests lithium may decrease risk of developing dementia

March 18, 2022

Photo of eye: Image by Cindy Parks from Pixabay.

Researchers eye up new gene therapy trial that could reverse hereditary blindness

September 1, 2021

Link between amino acid and a range of common diseases could help predict personal risk

August 24, 2021

Previous Next

Neuroscience Case Studies

2 people. 1 conducting an eye exam on the other using machinery

Gene therapy for inherited blindness

October 16, 2024

One person holding a thumb to the other persons head

Brain repair in multiple sclerosis

October 16, 2024

Improving the outcome from head injury

October 16, 2024

Tablets - Image from Cambridge University Health Partners

Alemtuzumab in Multiple Sclerosis

October 16, 2024

Link between amino acid and a range of common diseases could help predict personal risk

October 16, 2024

Previous Next

Neuroscience Publications

Integrated omics reveals disease-associated radial glia-like cells with epigenetically dysregulated interferon response in multiple sclerosis

October 10, 2025

Quantitative susceptibility mapping at 7 T in COVID-19: brainstem effects and outcome associations

October 9, 2024

Decompressive Craniectomy versus Craniotomy for Acute Subdural Hematoma

May 10, 2023

Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses

September 6, 2022

Socio-economic disadvantage is associated with alterations in brain wiring economy

June 16, 2022

The NIHR BRC: Cambridge is part of the NIHR and hosted by Cambridge University Hospitals NHS Foundation Trust in partnership with the University of Cambridge. We are at the heart of the Cambridge Biomedical Campus, Europe’s largest health research area.

Contact Us

NIHR Biomedical Research Centre: Cambridge
Box 277
Hills Road
Cambridge
CB2 0QQ

Tel: 01223 348490

NIHR Cambridge Biomedical Research Centre

@cambridgebrc ·

25 Aug

Congrats to @NIHR20 Research Leaders Prizewinners @CambridgeCRF Operations Director Caroline Saunders & @Cambridge_Uni & @CUH_NHS Neurosurgeon Benjamin Davies, who've both won awards for their leadership skills & commitment to patient-centred research: https://bit.ly/4y0HVFx

Reply on Twitter 2092249059863970201 Retweet on Twitter 2092249059863970201 Like on Twitter 2092249059863970201 4 Twitter 2092249059863970201

Retweet on Twitter NIHR Cambridge Biomedical Research Centre Retweeted

National Institute for Health and Care Research

Verified account @nihrresearch ·

21 Aug

Are you looking for guidance on setting up a clinical trial? Look no further!

The #CTToolkit is an interactive colour-coded routemap that provides guidance on legal and best practice requirements. Bursting with advice, it's a must-see for any aspiring researcher ➡️

Reply on Twitter 2090755707314245944 Retweet on Twitter 2090755707314245944 6 Like on Twitter 2090755707314245944 9 Twitter 2090755707314245944

Retweet on Twitter NIHR Cambridge Biomedical Research Centre Retweeted

Medicine at Cambridge

@medcambridge ·

20 Aug

The Lung Immune Challenge Study, led by @Akhilesh_Jha (@HLRI_Cambridge), has reached a milestone with the final participant completing the first phase designed to investigate how immune systems respond to viral lung infections.

➡️ https://buff.ly/tXrD5v8

@The_MRC @CambridgeBRC

Reply on Twitter 2090394450971238494 Retweet on Twitter 2090394450971238494 3 Like on Twitter 2090394450971238494 6 Twitter 2090394450971238494

Retweet on Twitter NIHR Cambridge Biomedical Research Centre Retweeted

National Institute for Health and Care Research

Verified account @nihrresearch ·

18 Aug

Learn about two upcoming career development awards that can support you in undertaking short placements in another part of NIHR or a local authority to enhance your research training experience and academic career development.

📅 Join our webinar from 12-1pm on 3 September to

Reply on Twitter 2089610127737327888 Retweet on Twitter 2089610127737327888 5 Like on Twitter 2089610127737327888 8 Twitter 2089610127737327888

NIHR Cambridge Biomedical Research Centre

@cambridgebrc ·

12 Aug

📣 Only 20 places left for each session❗️

Whether you’re new to PPI, want to improve your knowledge & skills we’ve got the session for you!

These FREE events are only available to East Anglia researchers - tickets for other regions are now fully booked! http://bit.ly/Trg4PPI

Reply on Twitter 2087509212653822457 Retweet on Twitter 2087509212653822457 Like on Twitter 2087509212653822457 1 Twitter 2087509212653822457

NIHR Cambridge Biomedical Research Centre

@cambridgebrc ·

10 Aug

📣 Full day of Patient & Public Involvement (PPI) training available❗️

👩‍🔬👨‍🔬 Are you a health researcher❓
🧑‍🤝‍🧑 New PPI❓
📍 Located in #EastAnglia❓
👍 We’ve got the training day for you!

Join us on 2 Sept 9.30am-4pm, West Hub, Cambridge.
Book https://bit.ly/4yUOx9L

Reply on Twitter 2086731822499602435 Retweet on Twitter 2086731822499602435 Like on Twitter 2086731822499602435 1 Twitter 2086731822499602435

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Neuroscience

This Theme’s Focus

Theme Lead

Professor Alasdair Coles

Here are some of the conditions we are researching:

Brain inflammation

Rare inherited neurological diseases

Traumatic brain injury (TBI)

Latest News

Neuroscience Case Studies

Neuroscience Publications

Contact Us

Useful Links